Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12...45678910111213141516»
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    [VIRTUAL] Vericiguat: A QTc interval study in patients with coronary artery disease () -  Jul 6, 2021 - Abstract #ESC2021ESC_3157;    
    P1
    Conclusion This study supports the assessment that administration of vericiguat 10 mg is not associated with clinically meaningful QTc prolongation. These data contribute to the overall safety profile of vericiguat for the treatment of patients with HF.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    [VIRTUAL] Leveraging translational approaches for accelerated clinical development of vericiguat () -  Jul 6, 2021 - Abstract #ESC2021ESC_3151;    
    Conclusions Our novel translational approach combining popPK/PD analyses of other sGC stimulators with PBPK modelling enabled vericiguat to move directly from Phase 1 to Phase 2b, reducing development time by ~2 years. PK and safety results from Phase 2b (SOCRATES-REDUCED) and Phase 3 (VICTORIA) trials confirmed that use of this translational approach to predict dose ranges of vericiguat was successful.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    [VIRTUAL] A concentration-QTc analysis of vericiguat () -  Jul 6, 2021 - Abstract #ESC2021ESC_3090;    
    P1
    Conclusion Based on the presented analysis, a clinically meaningful QT prolongation was robustly excluded within the plasma concentration range associated with the recommended target dose of vericiguat 10 mg. The C-QTc analysis supports the conclusion of the primary study statistical analysis that administration of vericiguat between 2.5 and 10 mg is not associated with a clinically meaningful QTc prolongation.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    [VIRTUAL] New therapies for patients following a worsening HF event () -  Jul 6, 2021 - Abstract #ESC2021ESC_1630;    
    Sponsored by Bayer AG Discuss the high event rates and unmet need in patients following a worsening HF event. Review the clinical benefits of vericiguat in this patient population and its potential role in the current treatment landscape.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical, Journal:  Vericiguat in patients with heart failure and reduced ejection fraction. (Pubmed Central) -  Jun 29, 2021   
    Predictive models developed in a large diverse clinical trial with comprehensive clinical and laboratory baseline data-including novel measures-performed well in high-risk HF patients who were receiving excellent guideline-based clinical care. Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    [VIRTUAL] Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial (ROOM 1) -  Jun 14, 2021 - Abstract #HEARTFAILURE2021HEART_FAILURE_688;    
    On behalf: on behalf of the VICTORIA Study Group Background: While safety and tolerability of vericiguat was established in the overall VICTORIA population, it remains unknown if there is vulnerability to symptomatic hypotension in some patient subgroups, such as older patients, those with lower baseline systolic blood pressure (SBP), or those concurrently taking the angiotensin receptor neprilysin inhibitor sacubitril/valsartan. These data demonstrate vericiguat’s efficacy regardless of baseline SBP and support vericiguat’s safety in a broad population of patients with worsening HFrEF, even among those predisposed to hypotension.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. (Pubmed Central) -  May 25, 2021   
    Sodium glucose cotransporter 2 inhibitors, vericiguat, and omecamtiv mecarbil are novel agents that promise to blunt the high residual risk of heart failure with reduced ejection fraction. We review the vast knowledge base that has rapidly materialized for these agents and is poised to shape the current and future trends and recommendations in heart failure pharmacotherapy.